Miikka Korja1, Rahul Raj1, Karri Seppä2, Tapio Luostarinen2, Nea Malila2, Matti Seppälä1, Hanna Mäenpää3, Janne Pitkäniemi2. 1. Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 2. Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland. 3. Department of Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Abstract
BACKGROUND: We assessed population-level changes in glioblastoma survival between 2000 and 2013 in Finland, with focus on elderly patients (>70 y) in order to assess if changes in treatment of glioblastoma are reflected also in population-based survival rates. METHODS: We identified all patients (age ≥18 y) from the Finnish Cancer Registry (FCR) with a histopathological diagnosis of primary glioblastoma in 2000-2013. Patients were followed up until December 2015. The accuracy of register-based search of glioblastoma patients was internally validated. We report age-standardized relative survival ratios and relative excess risks (RERs) of death in 2000-2006 (pre-period) and 2007-2013 (post-period). RESULTS: We identified 2045 glioblastoma patients from the FCR. The accuracy of the FCR-based search was 97%. Median age was 63.3 years, and 42% were women. Incidence increased on average by 1.6% (P = 0.004) and median age by 0.4 years per calendar year. Between the pre- and post-periods, the proportion of patients >70 years increased from 24% to 27%. In >70-year-old patients, the median survival time increased from 3.6 months in 2000-2006 to 4.5 months in 2007-2013 (RER 0.82, 95% CI: 0.68-0.98). In ≤70-year-old patients, the median survival time increased from 9.3 months in 2000-2006 to 11.7 months in 2007-2013 (RER 0.74, 95% CI: 0.67-0.82). CONCLUSION: Despite the increased proportion of elderly glioblastoma patients, population-level survival of glioblastoma patients has improved since the year 2000. However, increasing incidence, increasing age of patients, and poor survival in elderly are alarming, and future studies should perhaps focus more on elderly.
BACKGROUND: We assessed population-level changes in glioblastoma survival between 2000 and 2013 in Finland, with focus on elderly patients (>70 y) in order to assess if changes in treatment of glioblastoma are reflected also in population-based survival rates. METHODS: We identified all patients (age ≥18 y) from the Finnish Cancer Registry (FCR) with a histopathological diagnosis of primary glioblastoma in 2000-2013. Patients were followed up until December 2015. The accuracy of register-based search of glioblastomapatients was internally validated. We report age-standardized relative survival ratios and relative excess risks (RERs) of death in 2000-2006 (pre-period) and 2007-2013 (post-period). RESULTS: We identified 2045 glioblastomapatients from the FCR. The accuracy of the FCR-based search was 97%. Median age was 63.3 years, and 42% were women. Incidence increased on average by 1.6% (P = 0.004) and median age by 0.4 years per calendar year. Between the pre- and post-periods, the proportion of patients >70 years increased from 24% to 27%. In >70-year-old patients, the median survival time increased from 3.6 months in 2000-2006 to 4.5 months in 2007-2013 (RER 0.82, 95% CI: 0.68-0.98). In ≤70-year-old patients, the median survival time increased from 9.3 months in 2000-2006 to 11.7 months in 2007-2013 (RER 0.74, 95% CI: 0.67-0.82). CONCLUSION: Despite the increased proportion of elderly glioblastomapatients, population-level survival of glioblastomapatients has improved since the year 2000. However, increasing incidence, increasing age of patients, and poor survival in elderly are alarming, and future studies should perhaps focus more on elderly.
Authors: Matthew Koshy; John L Villano; Therese A Dolecek; Andrew Howard; Usama Mahmood; Steven J Chmura; Ralph R Weichselbaum; Bridget J McCarthy Journal: J Neurooncol Date: 2011-10-09 Impact factor: 4.130
Authors: James R Perry; Normand Laperriere; Christopher J O'Callaghan; Alba A Brandes; Johan Menten; Claire Phillips; Michael Fay; Ryo Nishikawa; J Gregory Cairncross; Wilson Roa; David Osoba; John P Rossiter; Arjun Sahgal; Hal Hirte; Florence Laigle-Donadey; Enrico Franceschi; Olivier Chinot; Vassilis Golfinopoulos; Laura Fariselli; Antje Wick; Loic Feuvret; Michael Back; Michael Tills; Chad Winch; Brigitta G Baumert; Wolfgang Wick; Keyue Ding; Warren P Mason Journal: N Engl J Med Date: 2017-03-16 Impact factor: 91.245
Authors: Angelique E Sijben; John B McIntyre; Gloria B Roldán; Jacob C Easaw; Elizabeth Yan; Peter A Forsyth; Ian F Parney; Anthony M Magliocco; Hans Bernsen; J Gregory Cairncross Journal: J Neurooncol Date: 2008-04-09 Impact factor: 4.130
Authors: Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller Journal: Lancet Oncol Date: 2012-05-10 Impact factor: 41.316
Authors: Michael Youssef; Ethan B Ludmir; Jacob J Mandel; Akash J Patel; Ali Jalali; Jeffrey Treiber; Jimin Wu; Mary Frances McAleer; John F de Groot Journal: J Neurooncol Date: 2019-10-23 Impact factor: 4.130
Authors: Tomomi W Nobashi; Aaron T Mayer; Zunyu Xiao; Carmel T Chan; Aisling M Chaney; Michelle L James; Sanjiv S Gambhir Journal: Clin Cancer Res Date: 2021-09-21 Impact factor: 13.801
Authors: Amy Johnston; Nicola Creighton; Jonathon Parkinson; Eng-Siew Koh; Helen Wheeler; Elizabeth Hovey; Michael Rodriguez; David C Currow Journal: Neurooncol Pract Date: 2019-07-06
Authors: Michael Tin Chung Poon; Paul M Brennan; Kai Jin; Cathie L M Sudlow; Jonine D Figueroa Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300